NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Price, News & Analysis $13.99 -0.27 (-1.89%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.95 -0.04 (-0.29%) As of 08/1/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Seres Therapeutics Stock (NASDAQ:MCRB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Seres Therapeutics alerts:Sign Up Key Stats Today's Range$13.38▼$14.1050-Day Range$7.00▼$14.8552-Week Range$6.53▼$26.40Volume47,064 shsAverage Volume149,374 shsMarket Capitalization$122.13 millionP/E RatioN/ADividend YieldN/APrice Target$73.67Consensus RatingReduce Company Overview Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Read More Seres Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreMCRB MarketRank™: Seres Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 399th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingSeres Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Seres Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Seres Therapeutics are expected to decrease in the coming year, from ($0.38) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeres Therapeutics has a P/B Ratio of 8.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Seres Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.37% of the float of Seres Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Seres Therapeutics has recently increased by 24.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.14 Percentage of Shares Shorted13.37% of the float of Seres Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Seres Therapeutics has recently increased by 24.24%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.13 News SentimentSeres Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Seres Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for MCRB on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows2 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Seres Therapeutics' insider trading history. Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Stock News HeadlinesSeres Therapeutics: Speculative Gem Backed By SER‑155 FDA BreakthroughJuly 31, 2025 | seekingalpha.comSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025July 22, 2025 | globenewswire.comNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being quietly opened to the public, and former hedge fund firm manager Whitney Tilson believes this is the best chance in years to turn a small stake into huge gains. He's naming one $10 stock leading this "US: IPO" boom. | Stansberry Research (Ad)Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comChardan Capital Downgrades Seres Therapeutics (MCRB)May 9, 2025 | msn.comSeres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comSeres Therapeutics reports Q1 EPS $3.75, consensus $1.97May 7, 2025 | msn.comSee More Headlines MCRB Stock Analysis - Frequently Asked Questions How have MCRB shares performed this year? Seres Therapeutics' stock was trading at $16.62 at the start of the year. Since then, MCRB shares have decreased by 15.8% and is now trading at $13.99. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings results on Wednesday, May, 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $1.57. Read the conference call transcript. When did Seres Therapeutics' stock split? Seres Therapeutics shares reverse split on Tuesday, April 22nd 2025.The 1-20 reverse split was announced on Thursday, April 10th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Seres Therapeutics IPO? Seres Therapeutics (MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. Who are Seres Therapeutics' major shareholders? Top institutional investors of Seres Therapeutics include Vontobel Holding Ltd. (0.92%). Insiders that own company stock include Eric D Shaff, Thomas Desrosier, Matthew R Henn, Teresa L Young, David S Ege, Paula Cloghessy and Moltke Lisa Von. View institutional ownership trends. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include PayPal (PYPL), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Micron Technology (MU), QUALCOMM (QCOM) and NIO (NIO). Company Calendar Last Earnings5/07/2025Today8/03/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MCRB CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Price Target for Seres Therapeutics$73.67 High Price Target$200.00 Low Price Target$6.00 Potential Upside/Downside+426.6%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($4.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$140 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-41,084.76% Return on Assets-55.87% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book8.69Miscellaneous Outstanding Shares8,732,000Free Float8,322,000Market Cap$122.16 million OptionableOptionable Beta2.89 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MCRB) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredOut with the old (A.I.) - In with the new (E.I.)One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.